Treatment of subcutaneous phaeohyphomycosis and prospective follow-up of 17 kidney transplant recipients.
Subcutaneous phaeohyphomycosis in solid organ recipients may have an adverse outcome. We sought to describe the disease course, treatment, and outcome of allograft function in kidney transplant recipients with phaeohyphomycosis. Seventeen patients were followed for a mean period of 25.4 months to analyze the clinical response to treatment. There was no treatment failure or relapsing disease among 12 patients who completed treatment. Two patients were still in treatment with disease remission. One patient discontinued the study during treatment with partial remission, one died after finishing treatment with disease remission, and one was dropped from the study because contact was lost. Immunosuppressive regimens were not changed. Two of 17 patients had a significant reduction in allograft function. The follow-up time was short and the number of patients was small. The outcome of phaeohyphomycosis in kidney transplant recipients was favorable with minimal impact on renal allograft function.